Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.01

-2.9%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mudcat who wrote (18401)	4/1/1998 8:40:00 AM
From: Henry Niman	Read Replies (1) of 32384

Mudcat, It's not clear if LGND does or does not want the SRGN compound. They have been granted an extension on the decision. I agree that Targretin has advantages, but if DAB389-IL-2 is approved, it will probably be six months ahead of Targretin topical and possibly a year ahead of Targretin oral. It is certainly possible that the compounds could synergize. Treatment of AIDS is a good example. Patients receive combination therapy which works better than any of the monotherapies and the combinations cost considerably more. Therefore, even though all three compounds target the same population, there may not be that much competition. I expect combination therapy to play an increasing role in most diseases, especially cancer. I suspect that the side effects as well as longer launch times may be playing a role in LGND's request for an extension.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next